Effect of fenretinide and low-dose tamoxifen on insulin sensitivity in premenopausal women at high risk for breast cancer

Cancer Research

Volumn 68, Issue 22, 2008, Pages 9512-9518

  Johansson, Harriet ^a,e   Gandini, Sara ^a   Guerrieri Gonzaga, Aliana ^a   Iodice, Simona ^a   Ruscica, Massimiliano ^a   Bonanni, Bernardo ^a   Gulisano, Marcella ^c   Magni, Paolo ^a   Formelli, Franca ^b   Decensi, Andrea ^a,d  

^a UNIVERSITY OF MILAN   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c SAN BORTOLO HOSPITAL   (Italy)

^d GALLIERA HOSPITAL   (Italy)

^e Division of Cancer Prevention and Genetics   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FENRETINIDE; GLUCOSE; INSULIN; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CANCER INVASION; CANCER RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HIGH RISK POPULATION; HOMEOSTASIS MODEL ASSESSMENT; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MEASUREMENT; METABOLIC SYNDROME X; OBESITY; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ANTINEOPLASTIC AGENTS; BODY MASS INDEX; BREAST NEOPLASMS; CHOLESTEROL, HDL; DOUBLE-BLIND METHOD; FEMALE; FENRETINIDE; HUMANS; INSULIN RESISTANCE; INSULIN-LIKE GROWTH FACTOR I; LEPTIN; PREMENOPAUSE; RETINOL-BINDING PROTEINS, PLASMA; TAMOXIFEN;

EID: 56449104497     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-0553     Document Type: Article

References (50)

1. Gail MH, Costantino JP, Bryant J, et al. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 1999;91:1829-46.
2. Decensi A, Robertson C, Viale G, et al. A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers. J Natl Cancer Inst 2003;95:779-90.
3. Guerrieri-Gonzaga A, Robertson C, Bonanni B, et al. Preliminary results on safety and activity of a randomized, double-blind, 2 × 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in premenopausal women. J Clin Oncol 2006;24:129-35.
4. Mehta RG, Moon RC, Hawthorne M, Formelli F, and Costa A. Distribution of fenretinide in the mammary gland of breast cancer patients. Eur J Cancer 1991;27: 138-41.
5. Costa A, Malone W, Perloff M, et al. Tolerability of the synthetic retinoid Fenretinide (HPR). Eur J Cancer Clin Oncol 1989;25:805-8.
6. Rotmensz N, De Palo G, Formelli F, et al. Long-term tolerability of fenretinide (4-HPR) in breast cancer patients. Eur J Cancer 1991;27:1127-31.
7. Veronesi U, Mariani L, Decensi A, et al. Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. Ann Oncol 2006;17:1065-71.
8. Conley B, O'shaughnessy J, Prindiville S, et al. Pilot trial of the safety, tolerability, and retinoid levels of N-(4-hydroxyphenyl) retinamide in combination with tamoxifen in patients at high risk for developing invasive breast cancer. J Clin Oncol 2000;18:275-83.
9. Lorincz AM, Sukumar S. Molecular links between obesity and breast cancer. Endocr Relat Cancer 2006;13: 279-92.
10. Stoll BA. Western nutrition and the insulin resistance syndrome: a link to breast cancer. Eur J Clin Nutr 1999; 53:83-7.
11. Yang Q, Graham TE, Mody N, et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005;436:356-62.
12. Grey AB, Stapleton JP, Evans MC, Reid IR. The effect of the anti-estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women. J Clin Endocrinol Metab 1995;80:3191-5.
13. Bagdade JD, Wolter J, Subbaiah PV, Ryan W. Effects of tamoxifen treatment on plasma lipids and lipoprotein lipid composition. J Clin Endocrinol Metab 1990;70: 1132-5.
14. Veronesi U, Maisonneuve P, Rotmensz N, et al. Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. JNCI Journal of the National Cancer Institute 2007;99:727-37.
15. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.
16. Bonora E, Kiechl S, Willeit J, et al. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes 1998;47:1643-9.
17. Formelli F, Clerici M, Campa T, et al. Five-year administration of fenretinide: pharmacokinetics and effects on plasma retinol concentrations. J Clin Oncol 1993;11:2036-42.
18. SAS Institute Inc. SAS/STATTMUser' s Guide. USA: Cary, NC: SAS Institute Inc. SAS Institute 1990.
19. Vona-Davis L, Howard-McNatt M, Rose DP. Adiposity, type 2 diabetes and the metabolic syndrome in breast cancer. Obes Rev 2007;8:395-408.
20. Goodwin PJ, Ennis M, Bahl M, et al. High insulin levels in newly diagnosed breast cancer patients reflect underlying insulin resistance and are associated with components of the insulin resistance syndrome. Breast Cancer Res Treat. Epub 2008 Apr 25.
21. Bruning PF, Bonfrer JM, Van Noord PA, Hart AA, de Jong-Bakker M, Nooijen WJ. Insulin resistance and breast-cancer risk. Int J Cancer 1992;52:511-6.
22. Fair AM, Dai Q, Shu XO, et al. Energy balance, insulin resistance biomarkers, and breast cancer risk. Cancer Detect Prev 2007;31:214-9.
23. Hu X, Juneja SC, Maihle NJ, Cleary MP. Leptin-a growth factor in normal and malignant breast cells and for normal mammary gland development. J Natl Cancer Inst 2002;94:1704-11.
24. Somasundar P, Yu AK, Vona-Davis L, McFadden DW. Differential effects of leptin on cancer in vitro . J Surg Res 2003;113:50-5.
25. Cleary MP, Juneja SC, Phillips FC, Hu X, Grande JP, Maihle NJ. Leptin receptor-deficient MMTV-TGF-α/ Lepr(db)Lepr(db) female mice do not develop oncogene-induced mammary tumors. Exp Biol Med Maywood 2004;229:182-93.
26. Cleary MP, Phillips FC, Getzin SC, et al. Genetically obese MMTV-TGF-α/Lep(ob)Lep(ob) female mice do not develop mammary tumors. Breast Cancer Res Treat 2003;77:205-15.
27. Vona-Davis L, Rose DP. Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression. Endocr Relat Cancer 2007;14:189-206.
28. Metzger D, Imai T, Jiang M, et al. Functional role of RXRs and PPARg in mature adipocytes. Prostaglandins Leukot Essent Fatty Acids 2005;73:51-8.
29. Graham TE, Wason CJ, Bluher M, Kahn BB. Shortcomings in methodology complicate measurements of serum retinol binding protein (RBP4) in insulinresistant human subjects. Diabetologia 2007;50:814-23.
30. Graham TE, Yang Q, Bluher M, et al. Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 2006;354:2552-63.
31. Gamble MV, Ramakrishnan R, Palafox NA, Briand K, Berglund L, and Blaner WS. Retinol binding protein as a surrogate measure for serum retinol: studies in vitamin A-deficient children from the Republic of the Marshall Islands. Am J Clin Nutr 2001;73:594-601.
32. Formelli F, Carsana R, Costa A, et al. Plasma retinol level reduction by the synthetic retinoid fenretinide: a one year follow-up study of breast cancer patients. Cancer Res 1989;49:6149-52.
33. Qi Q, Yu Z, Ye X, et al. Elevated retinol-binding protein 4 levels are associated with metabolic syndrome in Chinese people. J Clin Endocrinol Metab 2007;92:4827-34.
34. Gavi S, Qurashi S, Stuart LM, et al. Influence of age on the association of retinol-binding protein 4 with metabolic syndrome. Obesity Silver Spring 2008;16: 893-5.
35. Elisaf MS, Nakou K, Liamis G, Pavlidis NA. Tamoxifen-induced severe hypertriglyceridemia and pancreatitis. Ann Oncol 2000;11:1067-9.
36. Hozumi Y, Kawano M, Miyata M. Severe hypertriglyceridemia caused by tamoxifen-treatment after breast cancer surgery. Endocr J 1997;44:745-9.
37. Kanel KT, Wolmark N, Thompson PD. Delayed severe hypertriglyceridemia from tamoxifen. N Engl J Med 1997;337:281.
38. Bruno S, Maisonneuve P, Castellana P, et al. Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial. BMJ 2005;330:932.
39. Guvakova MA, Surmacz E. Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cells. Cancer Res 1997;57:2606-10.
40. Kleinman D, Karas M, Danilenko M, et al. Stimulation of endometrial cancer cell growth by tamoxifen is associated with increased insulin-like growth factor (IGF)-I induced tyrosine phosphorylation and reduction in IGF binding proteins. Endocrinology 1996;137: 1089-95.
41. Agarwal N, Sharma BC. Insulin resistance and clinical aspects of non-alcoholic steatohepatitis (NASH). Hepatol Res 2005;33:92-6.
42. Best L. Inhibition of glucose-induced electrical activity by 4-hydroxytamoxifen in rat pancreatic β-cells. Cell Signal 2002;14:69-73.
43. Lipscombe LL, Goodwin PJ, Zinman B, McLaughlin JR, Hux JE. Increased prevalence of prior breast cancer in women with newly diagnosed diabetes. Breast Cancer Res Treat 2006;98:303-9.
44. Pasanisi P, Berrino F, De Petris M, Venturelli E, Mastroianni A, Panico S. Metabolic syndrome as a prognostic factor for breast cancer recurrences. Int J Cancer 2006;119:236-8.
45. Eliassen AH, Missmer SA, Tworoger SS, et al. Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. J Natl Cancer Inst 2006;98:1406-15.
46. Kaaks R, Berrino F, Key T, et al. Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). J Natl Cancer Inst 2005;97:755-65.
47. Micheli A, Muti P, Secreto G, et al. Endogenous sex hormones and subsequent breast cancer in premenopausal women. Int J Cancer 2004;112:312-8.
48. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88.
49. Bernstein L, Deapen D, Cerhan JR, et al. Tamoxifen therapy for breast cancer and endometrial cancer risk. J Natl Cancer Inst 1999;91:1654-62.
50. Decensi A, Maisonneuve P, Rotmensz N, et al. Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trial. Circulation 2005;111: 650-6.